

Trastuzumab biosimilar HLX02 versus reference trastuzumab in the treatment of  
metastatic HER2-positive breast cancer: a model-based

Expert Review of Pharmacoeconomics and Outcomes Research  
, 1-10

DOI: 10.1080/14737167.2022.2107506

Citation Report

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------